Principle Investigator – Duxin Sun
Dr. Duxin Sun is the Associate Dean for Research in the College of Pharmacy at the University of Michigan. He is the Charles Walgreen Jr. Professor of Pharmacy and Professor of Pharmaceutical Sciences. Dr. Sun serves as the Director of Pharmacokinetics (PK) Core. Dr. Sun also has joint appointment in the Chemical Biology program, the Interdisciplinary Medicinal Chemistry program, and University of Michigan’s Comprehensive Cancer Center. Dr. Sun received broad training in Pharmaceutical Sciences (PhD), Molecular Biology (visiting scientist), Pharmacology (MS) and Pharmacy (BS).
Dr. Sun’s research interests focus on drug development, nanomedicine and pharmacokinetics. Dr. Sun has experience in both academia and pharmaceutical industry. Dr. Sun has published more than 260 papers (H-index 67), mentored 37 PhD students and 70 postdoctoral fellows/visiting scientists. Dr. Sun is a Fellow of American Association of Pharmaceutical Scientists (AAPS). Dr. Sun served on FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee. Dr. Sun has served on study sections for NIH and FDA.
Research Introduction to General Public: Drug Development and NanoMedicine
1. Why Most Anti-Cancer NanoMedicines Failed to Show Superior Clinical Efficacy and How to Improve It to Achieve Long-Term Tumor Remission?
2. Why 90% of Drug Development Fails and How to Improve It?
3. Why Most Anticancer Vaccines only Achieved Short-Term Effect and How to Improve It to Achieve Long-Term Efficacy?
4. What Are the Differences in Microbiome, Bile Salts, and Drug Release Between Human Small Intestine and Colon?